Literature DB >> 15338197

Hemodynamic assessment of splenomegaly in beta-thalassemia patients undergoing splenectomy.

Athanasios Aessopos1, Dimitrios Farmakis, Maria Tsironi, Spyros Deftereos, Stergios Tassiopoulos, Konstantinos Konstantopoulos, John Rombos, Efstathios Papalambros.   

Abstract

Splenomegaly is a common finding in beta-thalassemia; however, its hemodynamic features and its potential correlations with high output state and hepatic disorders, both also frequent in thalassemia, have not yet been assessed in these patients. Eight beta-thalassemia patients with the indication for splenectomy and no symptoms or signs of heart disease, aged 25.6+/-5.5 years, were studied. Preoperative assessment included hematological profile, liver biology, hepatitis virus serology, and echocardiography. During splenectomy, splenic artery blood flow and splenic vein pressure were directly measured and liver biopsies were taken. Preoperative echocardiographic data were compared with those of 34 healthy controls. The preoperative cardiac index was significantly elevated in patients (4.8+/-1.3 vs 3.4+/-1.1 l/min per m2 in controls, p<0.001). Splenic blood flow, although increased, was not particularly high, being 285+/-56 ml/min or 0.13+/-0.04 ml/min per g of splenic mass, representing 4.1+/-0.9% of total cardiac output (CO). Splenic vein pressure was considerably elevated (29.7+/-5.5 cmH2O). Hepatic fibrosis, iron deposition, and extramedullary foci were found in all eight biopsies. Serology was positive in five of eight cases. beta-thalassemia patients with extensive splenomegaly requiring splenectomy are characterized by high output state, increased splenic blood flow, which probably makes a limited contribution to CO elevation, and portal hypertension, manifest by increased splenic vein pressure and hepatic histopathological abnormalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338197     DOI: 10.1007/s00277-004-0934-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  4 in total

1.  Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.

Authors:  Nuntiya Somparn; Upa Kukongviriyapan; Wichittra Tassaneeyakul; Arunee Jetsrisuparb; Veerapol Kukongviriyapan
Journal:  Eur J Clin Pharmacol       Date:  2006-11-21       Impact factor: 2.953

2.  Pancytopaenia and an abdominal mass.

Authors:  Kerry A Layne; Ian Starke
Journal:  JRSM Short Rep       Date:  2010-08-31

3.  Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management.

Authors:  Athanasios Aessopos; Vasilios Berdoukas
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-18       Impact factor: 2.576

4.  Non-invasive MRI biomarkers for the early assessment of iron overload in a humanized mouse model of β-thalassemia.

Authors:  Laurence H Jackson; Evangelia Vlachodimitropoulou; Panicos Shangaris; Thomas A Roberts; Thomas M Ryan; Adrienne E Campbell-Washburn; Anna L David; John B Porter; Mark F Lythgoe; Daniel J Stuckey
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.